JNJ

168.27

-0.78%↓

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

VEEV

291.04

+0.02%↑

JNJ

168.27

-0.78%↓

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

VEEV

291.04

+0.02%↑

JNJ

168.27

-0.78%↓

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

VEEV

291.04

+0.02%↑

JNJ

168.27

-0.78%↓

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

VEEV

291.04

+0.02%↑

JNJ

168.27

-0.78%↓

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

VEEV

291.04

+0.02%↑

Search

Novartis AG

Chiusa

117.59 0.37

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

116.09

Massimo

117.64

Metriche Chiave

By Trading Economics

Entrata

418M

4B

Vendite

660M

14B

P/E

Media del settore

16.639

38.156

EPS

2.42

Rendimento da dividendi

3.5

Margine di Profitto

28.18

Dipendenti

75,883

EBITDA

-5.8B

4.9M

Raccomandazioni

By TipRanks

Raccomandazioni

Neutrale

Previsioni per 12 mesi

-4.83% downside

Dividendi

By Dow Jones

Rendimento da dividendi

Media del settore

3.50%

2.50%

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-18B

221B

Apertura precedente

117.22

Chiusura precedente

117.59

Punteggio Tecnico

By Trading Central

Fiducia

Bearish Evidence

Novartis AG Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

17 lug 2025, 14:26 UTC

Utili

Novartis Launches Buyback of Up to $10 Billion, Lifts Profit Outlook -- 2nd Update

17 lug 2025, 06:49 UTC

Utili

Novartis Launches Buyback of Up to $10 Billion, Lifts Profit Outlook -- Update

17 lug 2025, 05:41 UTC

Utili

Novartis Lifts Profit Outlook After Growth in Sales, Earnings

11 giu 2025, 08:25 UTC

Acquisizioni, Fusioni, Takeovers

EQT, Sanofi Co-Led $135 Million Funding Round for Spanish Biotech Company SpliceBio

17 lug 2025, 11:36 UTC

Discorsi di Mercato

Novartis CEO Urges Europe to Reform Drug-Pricing System -- Market Talk

17 lug 2025, 11:26 UTC

Discorsi di Mercato

Novartis CEO Confident on Midterm Plan to Mitigate U.S. Tariff Hit -- Market Talk

17 lug 2025, 07:14 UTC

Discorsi di Mercato

Retirement of Well-Regarded Executive a Loss for Novartis -- Market Talk

17 lug 2025, 07:02 UTC

Discorsi di Mercato
Utili

Novartis's Results Look Impressive -- Market Talk

17 lug 2025, 05:09 UTC

Utili

Novartis 2Q Sales Grew 11% at Constant Currency

17 lug 2025, 05:08 UTC

Utili

Novartis: Kirsch Will Continue as CFO, Member of Executive Committee Until March 2026

17 lug 2025, 05:06 UTC

Utili

Novartis: Mehta's Appointment Is Effective March 2026

17 lug 2025, 05:05 UTC

Utili

Novartis: Harry Kirsch Retires After 22 Years With Company

17 lug 2025, 05:05 UTC

Utili

Novartis Names Mukul Mehta as CFO

17 lug 2025, 05:04 UTC

Utili

Analysts Saw Novartis 2Q Net Profit at $3.815B

17 lug 2025, 05:04 UTC

Utili

Analysts Saw Novartis 2Q Core Operating Profit at $5.75B

17 lug 2025, 05:04 UTC

Utili

Analysts Saw Novartis 2Q Sales at $14.17B

17 lug 2025, 05:04 UTC

Utili

Novartis 2Q Core Operating Profit $5.925B

17 lug 2025, 05:04 UTC

Utili

Novartis 2Q Oper Pft $4.86B

17 lug 2025, 05:03 UTC

Utili

Novartis 2Q Sales $14.05B

17 lug 2025, 05:01 UTC

Utili

Novartis: Buyback to Be Completed by End of 2027

17 lug 2025, 05:01 UTC

Utili

Novartis Starting Buyback of Up to $10B

17 lug 2025, 05:01 UTC

Utili

Novartis Backs 2025 Sales View

17 lug 2025, 05:01 UTC

Utili

Novartis Had Guided for Low Double-Digit Growth in Core Operating Profit at Constant Currency

17 lug 2025, 05:01 UTC

Utili

Novartis Expects 2025 Core Operating Profit to Grow by Low Teens at Constant Currency

17 lug 2025, 05:00 UTC

Utili

Novartis Raises 2025 Earnings View

17 lug 2025, 05:00 UTC

Utili

Novartis AG 2Q Adj EPS $2.42

17 lug 2025, 05:00 UTC

Utili

Novartis AG 2Q Net Pft $4B

17 lug 2025, 05:00 UTC

Utili

Novartis AG 2Q EPS $2.07

9 lug 2025, 10:59 UTC

Discorsi di Mercato

Pharma Companies Would Be Severely Hurt by 200% Tariff -- Market Talk

2 giu 2025, 14:17 UTC

Discorsi di Mercato

Novartis's Pluvicto Delivers Positive Results in Third Late-Stage Trial -- Market Talk

Confronto tra pari

Modifica del prezzo

Novartis AG Previsione

Obiettivo di Prezzo

By TipRanks

-4.83% in calo

Previsioni per 12 mesi

Media 111.79 USD  -4.83%

Alto 139.377 USD

Basso 88 USD

Basato su 4 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Novartis AG - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Neutrale

4 ratings

0

Acquista

3

Mantieni

1

Vendi

Punteggio Tecnico

By Trading Central

N/A / 112.63Supporto e resistenza

A breve termine

Bearish Evidence

A termine intermedio

Weak Bullish Evidence

A lungo termine

Strong Bullish Evidence

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Novartis AG

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. The company also provides Pluvicto, lutetium Lu 177 vipivotide tetraxetan, indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer; and Lutathera, lutetium Lu 177 dotatate, a prescription medicine used to treat adults and children aged 12 years and older with gastroenteropancreatic neuroendocrine tumors. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. The company has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. It also has a research collaboration and license agreement with Schrödinger, Inc. to identify and develop various therapeutic candidates; and a strategic collaboration with Vyriad, Inc. for the discovery and development for vivo chimeric antigen receptor T-cell therapies. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.